Brokerages Expect Johnson & Johnson (JNJ) to Announce $2.01 EPS

Equities research analysts expect that Johnson & Johnson (NYSE:JNJ) will announce earnings per share (EPS) of $2.01 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Johnson & Johnson’s earnings, with estimates ranging from $1.88 to $2.08. Johnson & Johnson posted earnings of $1.83 per share during the same quarter last year, which suggests a positive year over year growth rate of 9.8%. The firm is expected to announce its next earnings results before the market opens on Tuesday, April 17th.

According to Zacks, analysts expect that Johnson & Johnson will report full year earnings of $8.11 per share for the current financial year, with EPS estimates ranging from $8.08 to $8.20. For the next financial year, analysts expect that the business will report earnings of $8.63 per share, with EPS estimates ranging from $8.40 to $8.97. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Johnson & Johnson.

How to Become a New Pot Stock Millionaire

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.05. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. During the same period in the prior year, the firm posted $1.83 EPS. The company’s quarterly revenue was up 12.6% on a year-over-year basis.



A number of equities research analysts have recently commented on JNJ shares. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 price objective on the stock in a research note on Thursday, April 5th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price on the stock in a research note on Tuesday, January 23rd. Stifel Nicolaus increased their target price on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. Finally, Morgan Stanley cut their target price on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 10th. Five research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $144.23.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.22% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in JNJ. Landmark Financial Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares during the last quarter. Paradigm Financial Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after purchasing an additional 9 shares during the last quarter. Premier Asset Management LLC raised its holdings in shares of Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after purchasing an additional 12 shares during the last quarter. Lbmc Investment Advisors LLC increased its holdings in Johnson & Johnson by 0.4% during the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after buying an additional 14 shares during the last quarter. Finally, Halbert Hargrove Russell LLC increased its holdings in Johnson & Johnson by 0.4% during the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after buying an additional 15 shares during the last quarter. 67.23% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:JNJ traded down $2.14 during trading on Thursday, reaching $129.62. The stock had a trading volume of 7,608,596 shares, compared to its average volume of 7,896,124. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. Johnson & Johnson has a 52 week low of $120.95 and a 52 week high of $148.32. The firm has a market cap of $350,440.66, a P/E ratio of 17.77, a P/E/G ratio of 2.08 and a beta of 0.74.

COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Johnson & Johnson (JNJ) to Announce $2.01 EPS” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2018/04/24/brokerages-expect-johnson-johnson-jnj-to-announce-2-01-eps.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply